U.S. Markets closed

Two Day FDA Compliance Seminar: Ensuring Compliance with Advertising and Promotional Requirements for Drugs and Medical Devices (Minneapolis, MN, United States - November 14-15, 2019)

DUBLIN, Sept. 25, 2019 /PRNewswire/ -- The "Ensuring Compliance with Advertising and Promotional Requirements for Drugs and Medical Devices" conference has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

Federal regulation of the advertising and promotion of pharmaceuticals and medical devices reflects an aggressive attitude on the part of the regulators that demands, in turn, that industry be keenly aware of the legal and regulatory duties, as well as key recent trends in enforcement activities by the Federal Government. This course will explore in detail what FDA requires of drug and device firms as well as recent current hot buttons in FDA enforcement activity for the advertising arena.

What's at stake if your advertising and promotional efforts violate the law? Colossal fines - the latest was $3 Billion; criminal liability, including even prison time; and huge disruption in operations while dealing with federal probes into illegal marketing.

Learning Objectives:

Key goals of the conference will include learning:

  • The basics of FDA law and regulations governing advertising and promotion, as well as sister agencies such as the Federal Trade Commission, which shares jurisdiction with FDA on certain regulated products (e.g., OTC drugs).
  • The distinctions between labels, labeling and advertising and how that impacts FDA's powers, and
  • How to properly position Direct-to-Consumer (DTC) promotions
  • The Dos and Don'ts of promoting products on the internet, including social media sites such as Facebook and Twitter
  • The perils of off-label promotion, including criminal and civil actions that have led to multi-billion dollar settlements by regulated drug companies
  • Whether the First Amendment provides any insulation for truthful statements regarding regulated products;
  • When disseminating medical educational materials crosses the line into improper promotion; and
  • Key considerations on how to implement appropriate procedures and controls in your company to minimize the potential for regulatory action by the FDA or the FTC relative to promotion and advertising.

Who Should Attend:

Senior executives, directors, managers and those who have responsibility for implementing advertising and promotional activities, as well as those that have key collateral roles in reviewing advertising for drug and device firms, including officials from these areas within regulated companies:

  • Sales
  • Marketing
  • Medical Affairs
  • Legal
  • Regulatory
  • Compliance

Agenda:

Day 1

I. Understanding the Basics

  • Who Has Jurisdiction
  • Drugs & Biologics
  • Rx Drug Advertising
  • OTC Drug Advertising
  • Devices
  • Restricted
  • all other
  • Labeling vs. Advertising
  • Basic drug rules
  • Fair balance
  • Device rules
  • Intended use deviations
  • DTC advertising
  • Print
  • TV
  • Comparative Claims
  • Standard to support
  • Push to pursue CER
  • Detailing and Sampling
  • Is there still a future?
  • What can be said?
  • Danger of custom pieces
  • How FDA learns of violations
  • Keep your house clean or your competitors will rat you out

II. Scientific Exchange

  • Guidances on Dissemination of Scientific Information
  • Risks involved in Off-Label Statements
  • Procedural Requirements and Unsolicited Requests for Information

III. First Amendment

  • Understanding Commercial Speech Doctrine
  • FDA and the Regulation of Advertising

IV. Websites & Social Media

  • FDA Policies on the Internet
  • Recent FDA Enforcement Activities
  • How to Handle at the Company Levels

Day 2

V. Enforcement Trends

  • FDA Hot Buttons
  • Understating risk
  • Overstating effectiveness
  • FTC
  • POM Wonderful and substantiation
  • Private Litigation - Understanding
  • Lanham Act
  • State Unfair Competition

VI. False Claims Act and Criminal Liability

  • Review of Key Settlements
  • Responsible Corporate Official Liability

VII. Handling at the Company Level

  • Compliance Programs
  • Internal processes

For more information about this conference visit https://www.researchandmarkets.com/r/u5uz8a

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision

View original content:http://www.prnewswire.com/news-releases/two-day-fda-compliance-seminar-ensuring-compliance-with-advertising-and-promotional-requirements-for-drugs-and-medical-devices-minneapolis-mn-united-states---november-14-15-2019-300925354.html

  • How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
    Business
    Investor's Business Daily

    How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

    Each of the ratings that go into the Composite score represents calculations of vast amounts of data in IBD's decades-old database. How To Research Growth Stocks: Simplify The Analysis And the ratings focus on the factors most influential in the success of a stock, based on decades of market research. For example, we know from this research that current profit growth (the C in IBD's CAN SLIM investment system) is the single most important determinant of stock gains, even before stocks start major price runs.

  • Business
    BBC News

    Staff back at work in former Thomas Cook shops

    Former Thomas Cook staff go back to work in their travel shops.

  • Bank of America declares ‘the end of the 60-40’ standard portfolio
    Business
    MarketWatch

    Bank of America declares ‘the end of the 60-40’ standard portfolio

    Investors have long been told that the ideal portfolio should carry 60% of its holdings in equities and 40% in bonds, a mix that provides greater exposure to historically superior stock returns, while also granting the diversification benefits and lower risk of fixed-income investments. But in a research note published by Bank of America Securities, titled “The End of 60/40,” portfolio strategists Derek Harris and Jared Woodard argue that “there are good reasons to reconsider the role of bonds in your portfolio,” and to allocate a greater share toward equities.

  • United Airlines third-quarter earnings beat expectations
    Business
    Yahoo Finance Video

    United Airlines third-quarter earnings beat expectations

    Yahoo Finance's Emily McCormick joined The Final Round to discuss United Airlines third quarter earnings beat.

  • Pictures Raise Specter of Fake Evidence in 737 Max Crash Probe
    Finance
    Bloomberg

    Pictures Raise Specter of Fake Evidence in 737 Max Crash Probe

    The time displayed in photos of a computer screen in the cockpit of the Boeing Co. 737 Max indicated they had actually been taken before the repair was performed, according to a draft of the final crash report being prepared by Indonesia's National Transportation Safety Committee, portions of which were reviewed by Bloomberg News. Investigators were similarly unable to confirm the authenticity of other pictures in the packet, which were supposed to show how a piece of equipment near the jet's nose had been calibrated, according to the report. There were indications that the pictures depicted a different plane, according to two people familiar with the investigation.

  • What Kind Of Shareholders Own Sorrento Therapeutics, Inc. (NASDAQ:SRNE)?
    Business
    Simply Wall St.

    What Kind Of Shareholders Own Sorrento Therapeutics, Inc. (NASDAQ:SRNE)?

    A look at the shareholders of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Sorrento Therapeutics is a smaller company with a market capitalization of US$207m, so it may still be flying under the radar of many institutional investors.

  • Cannabis Stocks in the Green: APHA, WEED, CTST, ACB
    Business
    Market Realist

    Cannabis Stocks in the Green: APHA, WEED, CTST, ACB

    With a boost from Aphria's (APHA) impressive first-quarter earnings, cannabis stocks were trading higher today. The sector ETFs, the ETFMG Alternative Harvest ETF (MJ) and the Horizons Marijuana Life Sciences Index ETF (HMMJ), were up 6.3% and 5.6%, respectively. Aphria stock rises over 15%

  • Kroger adds restaurants made famous on M*A*S*H to two stores
    News
    American City Business Journals

    Kroger adds restaurants made famous on M*A*S*H to two stores

    A Toledo company whose restaurants were made famous by the hit TV series M*A*S*H has reached a deal to open two restaurants in Kroger Co. stores. Tony Packo's, the real restaurant that was a favorite of fictional character Klinger, who craved its Hungarian hot dogs with chili peppers while serving in the Korean War on M*A*S*H, will have a Kroger location by year-end. A second will be opening soon after that, Tony Packo's vice president in charge of restaurants Scott Radel told me.

  • Hedge Funds Have Never Been More Bullish On Nielsen Holdings plc (NLSN)
    Business
    Insider Monkey

    Hedge Funds Have Never Been More Bullish On Nielsen Holdings plc (NLSN)

    The following article will discuss the smart money sentiment towards Nielsen Holdings plc (NYSE:NLSN). Is Nielsen Holdings plc (NYSE:NLSN) a bargain? The smart money is taking an optimistic view.

  • Hedge Funds Have Never Been This Bullish On Snap Inc. (SNAP)
    Business
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Snap Inc. (SNAP)

    So, let's examine which hedge funds were among the top holders of the stock and which hedge funds were making big moves. More specifically, Slate Path Capital was the largest shareholder of Snap Inc. NYSE:SNAP), with a stake worth $270.4 million reported as of the end of March.

  • Will Bank of America Stock Keep Rising after Earnings?
    Business
    Market Realist

    Will Bank of America Stock Keep Rising after Earnings?

    Shares of Bank of America Corporation (BAC) have returned 1.6% over the past year, outperforming the US banking industry's loss of 2.2%. Over the past few days, I've seen several bullish bets suggesting that Bank of America stock could keep climbing higher in the coming weeks and months. Bank of America stock: Third-quarter earnings expectations and valuation The company is slated to report its third-quarter earnings tomorrow, on October 16, before the market opens.

  • Aurora Cannabis’s Price Target Cut by 30%
    Business
    Market Realist

    Aurora Cannabis’s Price Target Cut by 30%

    In September, 15 analysts were covering Aurora stock, and they had a consensus target price of 10.73 Canadian dollars. On October 15, seven analysts are covering Aurora stock on the NYSE with a consensus recommendation of “buy. quot; These analysts have set a consensus target price of $7.43 on the stock, implying an upside potential of 111.68% based on its last closing price.

  • Investors In Nordic American Tankers Limited (NYSE:NAT) Should Consider This, First
    Business
    Simply Wall St.

    Investors In Nordic American Tankers Limited (NYSE:NAT) Should Consider This, First

    Could Nordic American Tankers Limited (NYSE:NAT) be an attractive dividend share to own for the long haul? Investors are often drawn to strong companies with the idea of reinvesting the dividends. On the other hand, investors have been known to buy a stock because of its yield, and then lose money if the company's dividend doesn't live up to expectations.

  • Oxy Stock Offers the Buffett Experience (Sort Of)
    Business
    Bloomberg

    Oxy Stock Offers the Buffett Experience (Sort Of)

    Buffett's cash also helped Oxy avoid putting the deal to its own shareholders — although many appear to have voted it down anyway, in a manner of speaking: Oxy's stint in the doghouse partly reflects fear, with oil dropping just as Oxy's debt ballooned. For at least the next year or so, the equity story looks yoked to the twists and turns of the trade war, which is as unsettling as it sounds. More importantly, though, Oxy's bet on Anadarko has put it at loggerheads with what investors want from oil companies these days.

  • Hedge Funds Have Never Been This Bullish On Zynga Inc (ZNGA)
    Business
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Zynga Inc (ZNGA)

    With the first-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the second quarter. One of these stocks was Zynga Inc (NASDAQ:ZNGA). Is Zynga Inc (NASDAQ:ZNGA) ready to rally soon?

  • Should Investors Sell on Apple’s and AMD’s Stock Rally?
    Business
    Market Realist

    Should Investors Sell on Apple’s and AMD’s Stock Rally?

    Apple (AAPL) stock is reaching new highs on strong demand for the iPhone 11, and Advanced Micro Device (AMD) stock suddenly rose on new processor announcements in October. Apple and AMD stocks are trading near the higher end of their 52-week range. Is now a good time to jump in and buy?

  • Hedge Funds Have Never Been This Bullish On Ollie’s Bargain Outlet Holdings, Inc. (OLLI)
    Business
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Ollie’s Bargain Outlet Holdings, Inc. (OLLI)

    Is Ollie's Bargain Outlet Holdings, Inc. NASDAQ:OLLI) ready to rally soon? Investors who are in the know are taking an optimistic view.

  • Aphria soars after second profitable quarter
    Business
    Yahoo Finance Video

    Aphria soars after second profitable quarter

    Aphria shares are soaring after the cannabis company reported its second consecutive profitable quarter. Yahoo Finance's Emily McCormick and Alexis Christoforous discuss.

  • Why Nvidia Stock Could Keep Rising
    Business
    Market Realist

    Why Nvidia Stock Could Keep Rising

    Plus, some bullish options bets that would indicate that Nvidia stock may surge higher, rising by at least 11% in the coming weeks and months. Let's take a look at the company's valuation, options activity, and technical chart to see if NVDA is investable at the current levels. Nvidia's valuation Nvidia is expensive, even compared to an industry with demanding valuations.

  • Is NetApp (NASDAQ:NTAP) A Risky Investment?
    Business
    Simply Wall St.

    Is NetApp (NASDAQ:NTAP) A Risky Investment?

    Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously said that 'Volatility is far from synonymous with risk. The latest balance sheet data shows that NetApp had liabilities of US$3.18b due within a year, and liabilities of US$3.77b falling due after that.

  • What’s Expected for AT&T’s Third-Quarter Earnings
    Business
    Market Realist

    What’s Expected for AT&T’s Third-Quarter Earnings

    When Elliott disclosed its $3.2 billion stake in AT&T last month, the telecom stock rose to a new 52-week high of $38.80. However, it has been range bound since then. It will be interesting to see how AT&T's Q3 results affect its stock.

  • Is First Solar, Inc. (FSLR) A Good Stock To Buy?
    Business
    Insider Monkey

    Is First Solar, Inc. (FSLR) A Good Stock To Buy?

    FSLR was in 24 hedge funds' portfolios at the end of the second quarter of 2019. There were 23 hedge funds in our database with FSLR holdings at the end of the previous quarter. Our calculations also showed that FSLR isn't among the 30 most popular stocks among hedge funds (view the video below).

  • Do Directors Own Square, Inc. (NYSE:SQ) Shares?
    Business
    Simply Wall St.

    Do Directors Own Square, Inc. (NYSE:SQ) Shares?

    I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don't tell me what you think, tell me what you have in your portfolio. Square has a market capitalization of US$26b, so it's too big to fly under the radar.

  • Hedge Funds Have Never Been This Bullish On Planet Fitness Inc (PLNT)
    Business
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Planet Fitness Inc (PLNT)

    Junto Capital Management had $39.2 million invested in the company at the end of the quarter. Steven Boyd's Armistice Capital also initiated a $19.1 million position during the quarter. The other funds with brand new PLNT positions are David Fiszel's Honeycomb Asset Management, Paul Marshall and Ian Wace's Marshall Wace LLP, and Dmitry Balyasny's Balyasny Asset Management.

  • JPMorgan Beats Q3 Estimates, Low Rates Are a Concern
    Business
    Market Realist

    JPMorgan Beats Q3 Estimates, Low Rates Are a Concern

    The bank's revenues beat analysts' expectations due to higher IB (investment banking) revenues. The higher NII (net interest income) in the Cards and Consumer & Business Banking segment also supported the top line. Stronger-than-expected revenues drove JPMorgan Chase's bottom line, which continued to increase at a double-digit rate.